⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BHVN News
Biohaven Ltd.
IgA Nephropathy Clinical Trial Space Intensifies with 25+ Companies in Active Development | DelveInsight
globenewswire.com
NVS
VRTX
BIIB
VTRS
AZN
IONS
TAK
ARWR
BHVN
NVO
LLY
LXRX
XRTX
REGN
FMS
MDT
AMPH
DRCT
BMRC
MAZE
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
prnewswire.com
BHVN
Form 8-K
sec.gov
BHVN
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
prnewswire.com
BHVN
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
prnewswire.com
BHVN
Form 8-K
sec.gov
BHVN
Form 8-K
sec.gov
BHVN
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
prnewswire.com
BHVN
Form 8-K
sec.gov
BHVN
KCNQ2 Developmental and Epileptic Encephalopathy Market Research Report 2025-2035, Competitive Analysis of Biohaven, Xenon Pharma, Lundbeck, Praxis Precision Medicines, NeuShen Therapeutics
globenewswire.com
BHVN
XENE
PRAX